Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444314 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by CASI pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00444314 is a Phase 2 study that has completed, run by CASI pharmaceuticals. The registered enrollment target is 82 participants.
The verdict
NCT00444314, a Phase 2 study, has completed, sponsored by CASI pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on Sunitinib Malate.
Interventions
- DRUG Sunitinib Malate
- DRUG Panzem® NCD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00444314
The ClinicalTrials.gov registry entry for NCT00444314 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CASI pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib Malate is the first listed.
NCT00444314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00444314 about?
NCT00444314 is a clinical study titled "Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma". This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on Sunitinib Malate.
What is the current status of trial NCT00444314?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2007-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00444314?
The interventions under investigation include: Sunitinib Malate (DRUG), Panzem® NCD (DRUG).
Who is sponsoring clinical trial NCT00444314?
This trial is sponsored by CASI pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.